RLAY
Q4 2026 EPS Estimate
$-0.39
Nov 5, 2026 · Reports after close
Revenue Estimate
$2M

Analyst Sentiment

Wall St. Consensus
Buy
15 analysts·Moderate coverage
77
Score
15 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
17%
Buy
1493%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$18.00
-7.4%
Consensus
$27.50
+41.5%
Bull
$31.00
+59.5%
12-Month Target Range15 analysts
$18.00$27.50$31.00
Current $19.44Consensus
Current Price
$19.44
Upside to Consensus
$8.06

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+70.07%
EPS
FY2028
Rev+97.90%
EPS
FY2029
Rev+416.49%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$11M$18M$35M$183M$449M
Low$4M$8M$16M$85M$208M
High$19M$49M$97M$501M$1.23B
EBITDA Avg$-11M$-18M$-35M$-183M$-449M
Low$-19M$-49M$-97M$-501M$-1.23B
High$-4M$-8M$-16M$-85M$-208M
EBIT Avg$-11M$-18M$-35M$-183M$-449M
Low$-19M$-49M$-97M$-501M$-1.23B
High$-4M$-8M$-16M$-85M$-208M
Net Income Avg$-276M$-276M$-275M$-191M$-50M
Low$-297M$-300M$-301M$-623M$-164M
High$-255M$-251M$-250M$-58M$-15M
EPS Avg$-1.61$-1.62$-1.61$-1.11$-0.29
Low$-1.73$-1.75$-1.75$-3.63$-0.95
High$-1.49$-1.46$-1.46$-0.34$-0.09
Analysts (Rev / EPS)9 / 98 / 910 / 105 / 45 / 4
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$2M$7M$775,000$775,000$1M$19M$480,000$480,000
Low$590,651$444,074$82,249$82,249$106,128$2M$50,941$50,941
High$3M$19M$2M$2M$3M$49M$1M$1M
EBITDA Avg$-2M$-7M$-775,000$-775,000$-1M$-19M$-480,000$-480,000
Low$-3M$-19M$-2M$-2M$-3M$-49M$-1M$-1M
High$-590,651$-444,074$-82,249$-82,249$-106,128$-2M$-50,941$-50,941
EBIT Avg$-2M$-7M$-775,000$-775,000$-1M$-19M$-480,000$-480,000
Low$-3M$-19M$-2M$-2M$-3M$-49M$-1M$-1M
High$-590,651$-444,074$-82,249$-82,249$-106,128$-2M$-50,941$-50,941
Net Income Avg$-81M$-77M$-81M$-83M$-82M$-73M$-87M$-89M
Low$-89M$-89M$-243M$-248M$-245M$-220M$-262M$-268M
High$-73M$-66M$13M$13M$13M$12M$14M$14M
EPS Avg$-0.40$-0.38$-0.40$-0.41$-0.40$-0.36$-0.43$-0.44
Low$-0.44$-0.44$-1.20$-1.22$-1.21$-1.09$-1.29$-1.32
High$-0.36$-0.32$0.06$0.07$0.07$0.06$0.07$0.07
Analysts (Rev / EPS)6 / 86 / 83 / 33 / 43 / 33 / 44 / 44 / 5

Earnings Surprises

Recent Analyst Actions

Aug 20, 2026H.C. Wainwright
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
Target:$29.00
+39.8%from $20.74
Aug 7, 2026Barclays
Relay Therapeutics price target raised to $30 from $27 at Barclays
Target:$30.00
+51.9%from $19.75
Jul 21, 2026Goldman Sachs
Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs
Target:$31.00
+61.6%from $19.18
Jul 16, 2026Canaccord Genuity
Relay Therapeutics initiated with a Buy at Canaccord
Target:$29.00
+48.6%from $19.51
May 26, 2026Guggenheim
Relay Therapeutics (RLAY) PT Raised to $26 at Guggenheim
Target:$26.00
+92.2%from $13.53
May 26, 2026H.C. Wainwright
Relay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
Target:$28.00
+106.9%from $13.53
May 20, 2026Barclays
Relay Therapeutics price target raised to $27 from $21 at Barclays
Target:$27.00
+123.7%from $12.07
May 19, 2026UBS
Relay Therapeutics price target raised to $26 from $23 at Raymond James
Target:$26.00
+101.8%from $12.88
Apr 29, 2026H.C. Wainwright
Relay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
Target:$25.00
+91.9%from $13.03
Apr 28, 2026Oppenheimer
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
Target:$18.00
+20.4%from $14.95
Apr 28, 2026Wells Fargo
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
Target:$21.00
+40.5%from $14.95
Apr 28, 2026Goldman Sachs
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
Target:$22.00
+47.2%from $14.95
Mar 13, 2026Guggenheim
Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim
Target:$22.00
+103.4%from $10.81
Jan 26, 2026Oppenheimer
Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
Target:$14.00
+88.4%from $7.43
Dec 12, 2025Wells Fargo
Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Target:$13.00
+66.7%from $7.80
Sep 16, 2024H.C. Wainwright
Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright
Target:$19.00
+150.0%from $7.60
Sep 10, 2024Jefferies
Relay Therapeutics upgraded to Buy from Hold at Jefferies
Target:$16.00
+68.2%from $9.51
Sep 9, 2024Barclays
Relay Therapeutics price target raised to $17 from $14 at Barclays
Target:$17.00
+78.8%from $9.51
Sep 4, 2024Bank of America Securities
Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities
Target:$20.00
+212.0%from $6.41
May 10, 2024Barclays
Barclays Upgrades Relay Therapeutics (RLAY) to Overweight
Target:$15.00
+124.7%from $6.68
May 6, 2024Oppenheimer
Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer
Target:$25.00
+255.1%from $7.04
Apr 20, 2023Jefferies
Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold
Target:$12.50
+1.2%from $12.35
Feb 3, 2023Oppenheimer
Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33
Target:$33.00
+45.0%from $22.76
Sep 30, 2022Barclays
Relay Therapeutics initiated with an Equal Weight at Barclays
Target:$23.00
-0.6%from $23.14
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.